ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP75-20 Commercial Pharmacy Benefit Exclusion for Aralast®NP, Eylea®, Glassia®, Lucentis®, Prolastin®-C, and UpliznaTM
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 12, 2020
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 2031 - 2040 လၢ 4296 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP70-20 In-Home Test Kits 2020 Program Details for Medicare Advantage and SecureBlue Members
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 12, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
Upcoming policies effective October 5, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
Reduction Mammoplasty Commercial Pre-Authorization Request Form (Medical Policy IV-32) (PDF)
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P28R1-20 Update: Medical Oncology Drug Prior Authorization Updates for Fully Insured Commercial and Medicare Advantage Subscribers – eviCore Healthcare Specialty Utilization Management (UM) Program
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 03, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P57-20 Site of Service Program Updates for Selected Specialty Medical Drugs for Commercial Subscribers: Medical Policy XI-06
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 03, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P63-20 Prior Authorization Updates for Skilled Nursing Facility Admissions
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 03, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P55-20 New Prior Authorization Timeframes Required by Legislation
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 03, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P58-20 Hereditary Angioedema (HAE) Drug Prior Authorization Management Changes for generic Icatibant, Firazyr, Haegarda, and Takhzyro — Effective October 5, 2020
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 03, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P56-20 New Medical, Medical Drug and Behavioral Health Policy Management Updates—Effective October 5, 2020
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 03, 2020